What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Jan H.M. Schellens mostly deals with Pharmacology, Pharmacokinetics, Internal medicine, Drug and Oncology.
His Pharmacology research includes themes of Paclitaxel, Toxicity and Docetaxel.
He interconnects Area under the curve, Adverse effect, Chemotherapy and Dosing in the investigation of issues within Pharmacokinetics.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and DPYD.
His biological study deals with issues like ATP-binding cassette transporter, which deal with fields such as P-glycoprotein.
In his study, which falls under the umbrella issue of Oncology, Colorectal cancer and Cetuximab is strongly linked to Clinical trial.
His most cited work include:
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers (2735 citations)
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers (2735 citations)
- Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. (982 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Pharmacology, Pharmacokinetics, Internal medicine, Chromatography and Oncology.
His Pharmacology study combines topics from a wide range of disciplines, such as Paclitaxel and Toxicity.
His Pharmacokinetics study incorporates themes from Tolerability, Adverse effect, Neutropenia and Dosing.
His study brings together the fields of Gastroenterology and Internal medicine.
His study focuses on the intersection of Oncology and fields such as Capecitabine with connections in the field of DPYD.
His research investigates the link between Tandem mass spectrometry and topics such as Metabolite that cross with problems in Urine.
He most often published in these fields:
- Pharmacology (61.95%)
- Pharmacokinetics (54.84%)
- Internal medicine (46.87%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (46.87%)
- Oncology (32.22%)
- Pharmacokinetics (54.84%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Pharmacokinetics, Pharmacology and Cancer.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and DPYD.
The Oncology study combines topics in areas such as Colorectal cancer, Clinical trial, Trametinib and Prospective cohort study.
His Pharmacokinetics research incorporates themes from Tolerability, Pazopanib and Chromatography.
His research in Pharmacology intersects with topics in Intracellular, Tyrosine-kinase inhibitor and Cutaneous leishmaniasis.
His Cancer study integrates concerns from other disciplines, such as Lung cancer and Pathology.
Between 2016 and 2021, his most popular works were:
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer (277 citations)
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer (230 citations)
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer (230 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Jan H.M. Schellens mainly focuses on Internal medicine, Oncology, Pharmacology, Cancer and Pharmacokinetics.
In his work, Vomiting, Oral administration and Anesthesia is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine.
Jan H.M. Schellens combines subjects such as Clinical trial, Capecitabine, Dihydropyrimidine dehydrogenase and DPYD with his study of Oncology.
His Pharmacology research is multidisciplinary, incorporating elements of Miltefosine, Chemotherapy and Toxicity.
His Cancer study combines topics in areas such as Lung cancer, Drug approval and MEDLINE.
Jan H.M. Schellens has included themes like Tyrosine-kinase inhibitor, Pazopanib and Drug in his Pharmacokinetics study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
